Safety and efficacy of pegfilgrastim in pediatric oncology patients: The M.D. Anderson Cancer Center experience.

Abstract

8272 Background: The growth factor filgrastim (G-CSF) reduces the severity and duration of neutropenia in cancer patients. Due to its short half-life, it has to be injected daily, usually for 7-10 days, which is a special challenge in treating children. Pegfilgrastim, a pegylated form of G-CSF, has a long half-life and thus only has to be injected once per… (More)

Topics

  • Presentations referencing similar topics